TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans
TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease.
TreeFrog Therapeutics Enters Into Pioneering Research Collaboration in Immuno-Oncology With the University of Pittsburgh
TreeFrog Therapeutics has announced a research collaboration with the University of Pittsburgh focused on the potential of tertiary lymphoid structures (TLS) in immuno-oncology, an exciting emerging field in cancer research.
TreeFrog Publishes Results of First Successful Bioproduction of a Parkinson’s Disease Cell Therapy in Scalable Bioreactor in Neurotherapeutics Journal
TreeFrog Therapeutics, a regenerative medicine biotech focused on using its proprietary GMP compliant technology platform, C-Stem™, to develop life-saving cell therapies, today published an article in Neurotherapeutics, demonstrating the first successful bioproduction of a Parkinson’s Disease cell therapy in a scalable bioreactor, leading to full behavioral recovery 16 weeks after transplantation using a cryopreserved 3D microtissue format.
GAIA BioMedicine and TreeFrog Therapeutics Announce Collaboration for the Expansion of Allogeneic NK-like Cells Against Solid TumorsFUKUOKA, Japan and BORDEAUX, France, Feb. 15, 2023 (GLOBE NEWSWIRE) -- GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells.
